{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T22:23:31Z","timestamp":1780698211011,"version":"3.54.1"},"reference-count":42,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T00:00:00Z","timestamp":1543968000000},"content-version":"am","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T00:00:00Z","timestamp":1543968000000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Res &amp; Perspec"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    SMTP\u20107 (\n                    <jats:italic>Stachybotrys microspora<\/jats:italic>\n                    triprenyl phenol\u20107) is a small molecule that promotes thrombolysis and suppresses inflammation possibly through plasminogen modulation and soluble epoxide hydrolase (\n                    <jats:styled-content style=\"fixed-case\">sEH<\/jats:styled-content>\n                    ) inhibition, respectively. Here, we demonstrate an efficacy of\n                    <jats:styled-content style=\"fixed-case\">SMTP<\/jats:styled-content>\n                    \u20107 in a severe embolic stroke model in monkeys. The middle cerebral artery was embolized by an autologous blood clot. Saline,\n                    <jats:styled-content style=\"fixed-case\">SMTP<\/jats:styled-content>\n                    \u20107, or tissue\u2010type plasminogen activator (t\u2010\n                    <jats:styled-content style=\"fixed-case\">PA<\/jats:styled-content>\n                    ) (n\u00a0=\u00a05 in each group) was given after 3\u00a0hours, and neurologic deficit scoring and infarct characterization were performed after 24\u00a0hours. Hemorrhagic infarct\u2010accompanied premature death was observed for two animals in t\u2010\n                    <jats:styled-content style=\"fixed-case\">PA<\/jats:styled-content>\n                    group.\n                    <jats:styled-content style=\"fixed-case\">SMTP<\/jats:styled-content>\n                    \u20107 treatment significantly reduced the sizes of infarct by 65%, edema by 37%, and clot by 55% compared to saline treatment. Plasma levels of the products of plasminogen activation (plasmin\u2010\u03b1\n                    <jats:sub>2<\/jats:sub>\n                    \u2010antiplasmin complex) and\n                    <jats:styled-content style=\"fixed-case\">sEH<\/jats:styled-content>\n                    reaction (dihydroxyeicosatrienoic acid) in\n                    <jats:styled-content style=\"fixed-case\">SMTP<\/jats:styled-content>\n                    \u20107 group were 794% (\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0&lt;\u00a00.05) and 60% (\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0=\u00a00.085) compared to saline group, respectively. No significant changes in the plasma levels of\n                    <jats:styled-content style=\"fixed-case\">MMP<\/jats:styled-content>\n                    \u20109,\n                    <jats:styled-content style=\"fixed-case\">CRP<\/jats:styled-content>\n                    ,\n                    <jats:styled-content style=\"fixed-case\">MCP<\/jats:styled-content>\n                    \u20101, and S100B were found. There was an inverse correlation between plasmin\u2010\u03b1\n                    <jats:sub>2<\/jats:sub>\n                    \u2010antiplasmin complex level and infarct volume (\n                    <jats:italic>r<\/jats:italic>\n                    \u00a0=\u00a00.93,\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0&lt;\u00a00.05), suggesting a role of thrombolysis in the\n                    <jats:styled-content style=\"fixed-case\">SMTP<\/jats:styled-content>\n                    \u20107 action to limit infarct development. In conclusion,\n                    <jats:styled-content style=\"fixed-case\">SMTP<\/jats:styled-content>\n                    \u20107 is effective in treating severe embolic stroke in monkeys under conditions where t\u2010\n                    <jats:styled-content style=\"fixed-case\">PA<\/jats:styled-content>\n                    treatment tends to cause hemorrhagic infarct\u2010associated premature death.\n                  <\/jats:p>","DOI":"10.1002\/prp2.448","type":"journal-article","created":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T02:44:48Z","timestamp":1544064288000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Efficacy of\n                    <scp>SMTP<\/scp>\n                    \u20107, a small\u2010molecule anti\u2010inflammatory thrombolytic, in embolic stroke in monkeys"],"prefix":"10.1002","volume":"6","author":[{"given":"Eriko","family":"Suzuki","sequence":"first","affiliation":[{"name":"Department of Applied Biological Science Tokyo Noko University (Tokyo University of Agriculture and Technology) Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Division of Research and Development TMS Co., Ltd. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Yoshikawa","sequence":"additional","affiliation":[{"name":"Shin Nippon Biomedical Laboratories, Ltd. Kagoshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudai","family":"Kunikiyo","sequence":"additional","affiliation":[{"name":"Department of Applied Biological Science Tokyo Noko University (Tokyo University of Agriculture and Technology) Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Division of Research and Development TMS Co., Ltd. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3340-7312","authenticated-orcid":false,"given":"Keiji","family":"Hasumi","sequence":"additional","affiliation":[{"name":"Department of Applied Biological Science Tokyo Noko University (Tokyo University of Agriculture and Technology) Tokyo Japan"},{"name":"Division of Research and Development TMS Co., Ltd. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,12,5]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2017.11.010"},{"key":"e_1_2_9_3_1","first-page":"75","article-title":"Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke","volume":"10","author":"Chapman SN","year":"2014","journal-title":"Vasc Health Risk Manag"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1P525"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2011.89"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1159\/000353125"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-4658.2010.07783.x"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.53.241"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-9560-10-2"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000032"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.110.598359"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.588087"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/ja.2015.58"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2011.08.018"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.10131FP"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.06.039"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2014.07.004"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.2013.191"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-010-0542-5"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-011-0642-x"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2017.10.055"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.010033"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-012-0115-z"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-017-1667-0"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.2174\/157340310791658730"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.54.962"},{"key":"e_1_2_9_27_1","unstructured":"Hoffmann\u2010La Roche Limited.2018.Product Monograph ACTIVASE\u00aert\u2010PA alteplase for injection.http:\/\/www.rochecanada.com\/content\/dam\/roche_canada\/en_CA\/documents\/Research\/ClinicalTrialsForms\/Products\/ConsumerInformation\/MonographsandPublicAdvisories\/Activase\/Activase_AIS_PM_E.pdfAccessed November 16 2018."},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1661592"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0270(00)00351-4"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1981.54.6.0773"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-670117"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R800038-JLR200"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2009.10.008"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2016.10.020"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1155\/MI.2005.175"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000138730.03264.ac"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1989.120"},{"key":"e_1_2_9_38_1","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/S0022-3565(25)23980-5","article-title":"Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue\u2010type plasminogen activator (rt\u2010PA) in humans","volume":"235","author":"Verstraete M","year":"1985","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-20095-9"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.14019FP"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/ja.2012.29"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2507"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2015.10.011"}],"container-title":["Pharmacology Research &amp; Perspectives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fprp2.448","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.448","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/prp2.448","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.448","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/chorus\/v1\/articles\/10.1002%2Fprp2.448","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.448","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T09:35:05Z","timestamp":1775295305000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/prp2.448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1002\/prp2.448"],"URL":"https:\/\/doi.org\/10.1002\/prp2.448","archive":["Portico"],"relation":{},"ISSN":["2052-1707","2052-1707"],"issn-type":[{"value":"2052-1707","type":"print"},{"value":"2052-1707","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"2018-10-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00448"}}